Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC). In a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxaliplatin-ba...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-03, Vol.41 (7), p.1434-1443
Hauptverfasser:	Qin, Shukui, Chen, Zhendong, Fang, Weijia, Ren, Zhenggang, Xu, Ruocai, Ryoo, Baek-Yeol, Meng, Zhiqiang, Bai, Yuxian, Chen, Xiaoming, Liu, Xiufeng, Xiao, Juxiang, Ho, Gwo Fuang, Mao, Yimin, Wang, Xin, Ying, Jieer, Li, Jianfeng, Zhong, Wenyan, Zhou, Yu, Siegel, Abby B, Hao, Chunyi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Hepatocellular - drug therapy Double-Blind Method Humans Liver Neoplasms - drug therapy ORIGINAL REPORTS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!